AB041. Partial versus complete thymectomy for t1a (<5 cm) thymoma: a propensity-matched analysis of oncologic and long-term immune-associated outcomes
- 1Division of Thoracic Surgery, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA
- 2Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- 3Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
Abstract
Background: Accumulating evidence suggests that adult thymic preservation may have long-term oncologic and immunologic implications. Thymectomy has been associated with increased cancer and mortality, and intact thymic function linked to T-cell diversity and cancer immunotherapy response. Whether complete thymectomy is necessary for small, localized thymomas remains unknown. At two NCI-designated cancer centers, we compared oncologic, perioperative, and exploratory long-term immune-associated outcomes after partial (PT) versus complete thymectomy (CT).
Methods: We retrospectively identified 169 patients who underwent PT (n=32) or CT (n=137) for pT1a thymoma <5 cm from 2005–2025. Optimal full propensity-score matching yielded 29 PT and 131 CT patients matched on age, sex, race, smoking, prior cardiothoracic surgery, pulmonary and renal comorbidity, preoperative myasthenia gravis and autoimmune disease, prior malignancy, WHO histology, capsular invasion, and mediastinal pleural invasion. Recurrence was analyzed with death as a competing event. Long-term outcomes were retrospectively abstracted from institutional records and included new malignancy or autoimmune disease within five years and infection requiring hospitalization within ten years.
Results: Median follow-up was 5.1 years. R0 resection was achieved in all PT patients. No recurrences occurred after PT; recurrence did not differ between groups (P=0.55). There was no difference in OS (P=0.19, 5yOS: 100% PT, 94.7% CT). PT reduced median operative time by 43 minutes (97 vs. 140 minutes; P=0.001), while complication rates were similar (17.2% vs. 23.7%; P=0.47). One recurrent laryngeal and one phrenic nerve injury occurred after CT, both requiring operative repair; neither occurred after PT. New malignancy occurred in 13.8% vs. 13.7% (P=0.99), new autoimmune disease in 0% vs. 8.4% (P=0.22), infection requiring hospitalization in 6.9% vs. 10.7% (P=0.74), and new myasthenia gravis in 0% vs. 2.3% (P>0.99). Composite immune-associated morbidity was 20.7% vs. 27.5% (P=0.47).
Conclusions: Among selected patients with resected T1a thymoma <5 cm, PT was associated with shorter operative time and no observed recurrence, without significant differences in perioperative, oncologic, or long-term immune-associated outcomes. Limited sample size, low event rates, follow-up duration, and retrospective outcome ascertainment preclude conclusions regarding oncologic equivalence or immunologic benefit. These findings support prospective evaluation of thymus-preserving surgery with standardized surveillance and measures of thymic function.
Related
- Long-term oncologic outcomes associated with clinically significant anastomotic leakage after curative colorectal cancer surgery: Stage- and location-stratified analyses
- Risk‐Stratified Bilateral Tonsillectomy for Unilateral HPV‐Associated Tonsillar SCC: Oncologic and Functional Outcomes From a Single Institution
- Clinical Outcomes Associated With Intravenous Fluid Shortages in Emergency Department Patients: A Propensity Score Matched Cohort Study
- Internal Medicine-Led Multidisciplinary Co-Management is Associated with Improved Perioperative Outcomes in Elderly Patients with Hip Fracture: A Propensity Score Matched Study
- Concomitant acromioplasty is associated with enhanced structural healing, long-term durability, and functional outcomes in arthroscopic rotator cuff repair: a retrospective propensity score and causal machine-learning analysis.
BibTeX
@article{chandra2026ab041,
title = {{AB041. Partial versus complete thymectomy for t1a (<5 cm) thymoma: a propensity-matched analysis of oncologic and long-term immune-associated outcomes}},
author = {Raghav Chandra and Akshara Vykunta and Alexander Gregor and Amy M. Shui and Melissa H. Coleman and Johannes R. Kratz and James Huang and Matthew S. Skovgard},
journal = {Mediastinum},
year = {2026},
month = oct,
doi = {10.21037/med-26-ab041},
url = {https://doi.org/10.21037/med-26-ab041},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - AB041. Partial versus complete thymectomy for t1a (<5 cm) thymoma: a propensity-matched analysis of oncologic and long-term immune-associated outcomes
AU - Raghav Chandra
AU - Akshara Vykunta
AU - Alexander Gregor
AU - Amy M. Shui
AU - Melissa H. Coleman
AU - Johannes R. Kratz
AU - James Huang
AU - Matthew S. Skovgard
PY - 2026
DA - 2026/10/30
JO - Mediastinum
DO - 10.21037/med-26-ab041
UR - https://doi.org/10.21037/med-26-ab041
AB - Background: Accumulating evidence suggests that adult thymic preservation may have long-term oncologic and immunologic implications. Thymectomy has been associated with increased cancer and mortality, and intact thymic function linked to T-cell diversity and cancer immunotherapy response. Whether complete thymectomy is necessary for small, localized thymomas remains unknown. At two NCI-designated cancer centers, we compared oncologic, perioperative, and exploratory long-term immune-associated outcomes after partial (PT) versus complete thymectomy (CT). Methods: We retrospectively identified 169 patients who underwent PT (n=32) or CT (n=137) for pT1a thymoma <5 cm from 2005–2025. Optimal full propensity-score matching yielded 29 PT and 131 CT patients matched on age, sex, race, smoking, prior cardiothoracic surgery, pulmonary and renal comorbidity, preoperative myasthenia gravis and autoimmune disease, prior malignancy, WHO histology, capsular invasion, and mediastinal pleural invasion. Recurrence was analyzed with death as a competing event. Long-term outcomes were retrospectively abstracted from institutional records and included new malignancy or autoimmune disease within five years and infection requiring hospitalization within ten years. Results: Median follow-up was 5.1 years. R0 resection was achieved in all PT patients. No recurrences occurred after PT; recurrence did not differ between groups (P=0.55). There was no difference in OS (P=0.19, 5yOS: 100% PT, 94.7% CT). PT reduced median operative time by 43 minutes (97 vs. 140 minutes; P=0.001), while complication rates were similar (17.2% vs. 23.7%; P=0.47). One recurrent laryngeal and one phrenic nerve injury occurred after CT, both requiring operative repair; neither occurred after PT. New malignancy occurred in 13.8% vs. 13.7% (P=0.99), new autoimmune disease in 0% vs. 8.4% (P=0.22), infection requiring hospitalization in 6.9% vs. 10.7% (P=0.74), and new myasthenia gravis in 0% vs. 2.3% (P>0.99). Composite immune-associated morbidity was 20.7% vs. 27.5% (P=0.47). Conclusions: Among selected patients with resected T1a thymoma <5 cm, PT was associated with shorter operative time and no observed recurrence, without significant differences in perioperative, oncologic, or long-term immune-associated outcomes. Limited sample size, low event rates, follow-up duration, and retrospective outcome ascertainment preclude conclusions regarding oncologic equivalence or immunologic benefit. These findings support prospective evaluation of thymus-preserving surgery with standardized surveillance and measures of thymic function.
SN - 2522-6711
ER -